BI
BIOAF.US biOasis Technologies Inc
- Market cap
- USD 7.94K
- P/E
- -
- P/B
- 53.47x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to May 2023.
Is BIOAF.US undervalued?
Graham numberThe Graham number of biOasis Technologies Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
biOasis Technologies Inc fundamental analysis
No fundamental analysis for biOasis Technologies Inc yet.
biOasis Technologies Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About biOasis Technologies Inc
Bioasis Technologies Inc. operates as a biopharmaceutical company. The company utilizes its proprietary xB3 platform to deliver therapeutics across the blood-brain barrier and treat central nervous system disorders in areas of high unmet medical need. Bioasis Technologies Inc. is based in New Haven, Connecticut.
Full company profilebiOasis Technologies Inc financial statements
2023 annualized: Fiscal year 2023 is not finished. Income statement and cash flow are annualized from 1 quarter up to May 31, 2023, the balance sheet is the latest quarter. Figures change when the annual report is published.
biOasis Technologies Inc annual financial statements
| Item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2023 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 369K | 513K | 590K | 1.42M | 606K | 4.08M | 37.7K | - | - |
| Gross Profit | 0.00 | 0.00 | -54.7K | 83.1K | 122K | 1.41M | 606K | 2.84M | -1.19M | - | - |
| Operating Income | -3.64M | -2.84M | -2.56M | -2.99M | -5.24M | -6.24M | -5.19M | -858K | -4.82M | - | - |
| EBITDA | -3.59M | -2.79M | -2.51M | -2.94M | -5.22M | -4.79M | -4.54M | 441K | -3.54M | - | - |
| Net Income | -3.61M | -2.84M | -2.57M | -2.99M | -5.31M | -3.47M | -4.06M | 698K | -2.96M | - | - |
| EPS | -0.09 | -0.07 | -0.06 | -0.07 | -0.10 | -0.06 | -0.07 | 0.01 | -0.04 | - | - |
| Balance Sheet | |||||||||||
| Total Assets | 2.58M | 2.21M | 2.15M | 1.11M | 1.22M | 1.74M | 942K | 3.28M | 2.27M | - | - |
| Total Liabilities | 188K | 207K | 434K | 748K | 788K | 2.29M | 3.43M | 2.87M | 4.18M | - | - |
| Shareholders' Equity | 2.39M | 2.01M | 1.72M | 363K | 434K | -547K | -2.49M | 407K | -1.92M | - | - |
| Cash & Short-term Investments | 1.84M | 1.64M | 1.62M | 554K | 678K | 1.36M | 576K | 2.74M | 1.73M | - | - |
| Total Debt | - | - | - | - | - | - | 1.00M | 114K | 1.90M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -2.82M | -2.02M | -1.53M | -1.24M | -3.67M | -3.23M | -3.30M | 1.77M | -3.64M | - | - |
| Capital Expenditure | 677.75 | 750.00 | 2.46K | 43.5K | 108K | 2.06K | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Free Cash Flow | -2.82M | -2.02M | -1.53M | -1.24M | -3.78M | -3.23M | -3.30M | 1.77M | -3.64M | - | - |
| Ratios | |||||||||||
| ROE | -151.0% | -141.4% | -149.7% | -823.0% | -1,222.6% | - | - | 171.5% | - | - | - |
| ROA | -140.0% | -128.2% | -119.5% | -269.2% | -434.4% | -199.2% | -430.7% | 21.3% | -130.6% | - | - |
| Net Profit Margin | - | - | -697.0% | -583.0% | -899.9% | -244.3% | -669.0% | 17.1% | -7,846.5% | - | - |
| Debt to Equity | - | - | - | - | - | - | - | 0.28x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
biOasis Technologies Inc dividends
biOasis Technologies Inc has not paid dividends in the last 10 fiscal years.
Who owns biOasis Technologies Inc
- Insiders 2.05%
- Institutions 0.00%
- Public & others 97.95%
- Shares outstanding 79.4M
- Free float 78.1M
biOasis Technologies Inc company profile
- Company name
- biOasis Technologies Inc
- Ticker
- BIOAF.US
- ISIN
- CA09064N1033
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- February
- Address
- 157 Church Street, New Haven, CT, United States, 06510
- Phone
- 203 533 7082
- Website
- bioasis.us
About biOasis Technologies Inc
Bioasis Technologies Inc. operates as a biopharmaceutical company. The company utilizes its proprietary xB3 platform to deliver therapeutics across the blood-brain barrier and treat central nervous system disorders in areas of high unmet medical need. Bioasis Technologies Inc. is based in New Haven, Connecticut.
biOasis Technologies Inc management
5- Dr. Deborah Ann Rathjen B.Sc. (Hons.), FTSE, M.A.I.C.D., Ph.D., Q.C.CEO & President · born 1958
- Mr. David P. JenkinsChief Financial Officer · born 1962
- Mr. Graeme DickDirector of Investor Relations
- Mr. Aaron EltonDirector of Marketing
- Dr. Mei Mei TianVP & Head of External Research